Answers are grounded in this paper and cite their sources.
Observational study reveals circulating tissue thromboplastin release during femoral prosthesis impaction in total hip replacement, indicating procedural clot-activation risks.
An immunoradiometric assay for tissue thromboplastin has been established. Blood levels in 6 patients undergoing total hip replacement have been determined. In 3 patients, high levels of circulating apoprotein III were found at various stages of the operation, showing a release of tissue thromboplastin chiefly during impaction of the prosthesis into the femoral bone. The other 3 patients had low or undetectable levels.
No takes yet. Share an insight, caveat, or question.
Giercksky et al. (2008) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: